Accelerate Diagnostics, BioCheck Get FDA Emergency Use Authorization for COVID-19 Antibody Testing System

Aug 18, 2020

|

NEW YORK – Accelerate Diagnostics and BioCheck announced on Tuesday that it has received Emergency Use Authorization from the US Food and Drug Administration for a COVID-19 serology assay and test system.

The BioCheck SARS-CoV-2 IgM and IgG Combo Test and fully-automated MS-Fast instrument will be marketed and commercialized by Accelerate Diagnostics following a commercial supply and collaboration agreement the firms forged in April.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Accelerate Diagnostics, BioCheck Get FDA Emergency Use Authorization for COVID-19 Antibody Testing System

To read the full story....

Breaking News

Hologic Fiscal Q1 Revenues Rise 89 Percent as Dx Testing Demand Surges

Spectrum Solutions, UCLA Partner to Study Saliva-Based Early-Stage Lung Cancer Detection

T2 Biosystems Preliminary Q4 Revenues Grow 155 Percent, Miss Estimates

Abbott Q4 Diagnostics Revenues Up 111 Percent, FY20 Revenues Up 9 Percent

Siemens Healthineers Q1 Diagnostics Revenues Rise 17 Percent on Pandemic-Related Demand

Abbott Panbio SARS-CoV-2 Rapid Antigen Test Nabs CE Mark for Asymptomatic Screening, Self-Collection

Featured White Papers

After the Surge: Driving Sample Processing Efficiency of Coronavirus Samples

What's Popular?

Siemens Healthineers Q1 Diagnostics Revenues Rise 17 Percent on Pandemic-Related Demand

Ambry Genetics Gets FDA Emergency Use Authorization for Coronavirus Test

Infectious Disease Test Firm Talis Biomedical Files for IPO

Fluxergy Aiming to Provide Low-Cost, Multimodal Testing for SARS-CoV-2, Other Disease Targets

Lab Stakeholders Welcome Biden Moves on COVID-19 Testing, Suggest Additional Steps

Sponsorships